Controlling PRRS virus in the grow-finish period makes “cents” Economic losses of porcine reproductive and respiratory syndrome (PRRS) have been estimated at $664 million in the United States. Losses occurring in the grow-finishing period alone total $361.85 million, representing a profit loss of $4.32/pig.1,2 (Cost includes performance losses and cost of medication.)
Pigs infected with PRRS have significantly worse average daily gain (ADG) and higher mortalities compared to pigs remaining PRRS-negative through market (see below).2 The majority of the economic losses are due to decreased revenue from marketing fewer pounds of pork.
Vaccinating pigs 3 weeks of age or older with either Ingelvac PRRS® MLV vaccine or Ingelvac PRRS® ATP vaccine aids in the prevention of respiratory disease associated with PRRS. Talk to your Boehringer Ingelheim Vetmedica, Inc. representative about how Ingelvac PRRS® vaccines can help your herd.
- Holtkamp D, Kliebenstein J, Neumann E, et al. PRRS virus control or elimination: How to assess which is right for individual breeding herds. 53rd Annual George A. Young Swine Health and Management Conference. 2012;5–15.
- Assessment of the economic impact of porcine reproductive and respiratory syndrome virus on United States pork producers. J Swine Health Prod 2013;21(2):72–84.